Young Rok

3.7k total citations
117 papers, 1.2k citations indexed

About

Young Rok is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Young Rok has authored 117 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Hematology, 45 papers in Oncology and 38 papers in Pathology and Forensic Medicine. Recurrent topics in Young Rok's work include Lymphoma Diagnosis and Treatment (35 papers), Chronic Lymphocytic Leukemia Research (24 papers) and Chronic Myeloid Leukemia Treatments (17 papers). Young Rok is often cited by papers focused on Lymphoma Diagnosis and Treatment (35 papers), Chronic Lymphocytic Leukemia Research (24 papers) and Chronic Myeloid Leukemia Treatments (17 papers). Young Rok collaborates with scholars based in South Korea, United States and Ethiopia. Young Rok's co-authors include Hong Song, Young Ho Yun, Kyung Hae Jung, Jong Gwang Kim, Dae Seog Heo, Myung Kyung Lee, Sangyoon Park, Jong Soo Choi, Samyong Kim and Sang Kyun Sohn and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Young Rok

105 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Young Rok South Korea	20	503	348	254	232	209	117	1.2k
Sang Kyun Sohn South Korea	20	360 0.7×	168 0.5×	240 0.9×	309 1.3×	218 1.0×	61	1.2k
Jonas Paludo United States	16	611 1.2×	253 0.7×	295 1.2×	129 0.6×	139 0.7×	150	1.2k
Wen Liu‐Mares United States	20	397 0.8×	198 0.6×	225 0.9×	199 0.9×	251 1.2×	33	1.8k
Kathleen Donohue United States	18	469 0.9×	181 0.5×	284 1.1×	237 1.0×	86 0.4×	36	1.1k
Eun‐Kee Song South Korea	22	623 1.2×	183 0.5×	222 0.9×	80 0.3×	380 1.8×	80	1.4k
Charles F. LeMaistre United States	19	525 1.0×	355 1.0×	199 0.8×	593 2.6×	95 0.5×	48	1.2k
Rachel Hobson United Kingdom	18	198 0.4×	213 0.6×	349 1.4×	60 0.3×	223 1.1×	41	1.1k
Bruce G. Gordon United States	14	276 0.5×	301 0.9×	259 1.0×	348 1.5×	48 0.2×	43	915
Asim Belgaumi Saudi Arabia	18	305 0.6×	293 0.8×	301 1.2×	151 0.7×	63 0.3×	63	959
E Cadman United States	18	776 1.5×	267 0.8×	228 0.9×	198 0.9×	253 1.2×	39	1.6k

Countries citing papers authored by Young Rok

Since Specialization

Citations

This map shows the geographic impact of Young Rok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Young Rok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Young Rok more than expected).

Fields of papers citing papers by Young Rok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Young Rok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Young Rok. The network helps show where Young Rok may publish in the future.

Co-authorship network of co-authors of Young Rok

This figure shows the co-authorship network connecting the top 25 collaborators of Young Rok. A scholar is included among the top collaborators of Young Rok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Young Rok. Young Rok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kong, Jee Hyun, Junshik Hong, Ja Min Byun, et al.. (2025). Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study. Therapeutic Advances in Hematology. 16. 1584267121–1584267121. 2 indexed citations

Yhim, Ho‐Young, Yong Park, Jeong‐A Kim, et al.. (2024). Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study. The Korean Journal of Internal Medicine. 39(3). 501–512. 3 indexed citations

Park, Changhee, Ho Sup Lee, Ka‐Won Kang, et al.. (2024). Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nature Communications. 15(1). 2776–2776. 6 indexed citations

Jung, Sung‐Hoon, Je‐Jung Lee, Young Rok, et al.. (2024). Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study. Scientific Reports. 14(1). 24325–24325.

Lee, Ji Yun, Ji Hyun Kwon, Joon Young Hur, et al.. (2023). Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea. Cancer Research and Treatment. 56(2). 681–687. 4 indexed citations

Jung, Eun Hee, Ja Min Byun, Dong‐Yeop Shin, et al.. (2023). Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122). Cancer Medicine. 12(8). 9186–9193. 2 indexed citations

Baek, Dong Won, Han‐Seung Park, Sang Kyun Sohn, et al.. (2023). Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study. The Korean Journal of Internal Medicine. 38(5). 734–746. 5 indexed citations

Kim, Mihee, Je‐Jung Lee, Chang‐Ki Min, et al.. (2023). Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015). Annals of Hematology. 102(8). 2233–2240. 1 indexed citations

Kim, Sung‐Hyun, et al.. (2023). P658: DEVELOPMENT OF THE HIGHLY ACCURATE AND SENSITIVE METHOD USING THE CHIP-BASED DIGITAL PCR (LOAA) FOR THE DETECTION OF BCR::ABL1 TRANSCRIPTS DURING WHOLE PERIOD OF CHRONIC MYELOID LEUKEMIA TREATMENT. HemaSphere. 7(S3). e528827a–e528827a.

10.

Rok, Young, et al.. (2021). Sciatic nerve neurolymphomatosis as the initial presentation of primary diffuse large B-cell lymphoma: a rare cause of leg weakness. SHILAP Revista de lepidopterología. 38(3). 258–263. 2 indexed citations

11.

Shin, Hyejin, Dae Young Zang, Sung‐Hyun Kim, et al.. (2021). Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 21(6). e521–e529. 7 indexed citations

12.

Jung, Sung‐Hoon, Young Rok, Dae Sik Kim, et al.. (2020). Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. Yonsei Medical Journal. 61(6). 452–452.

13.

Shim, Ye Jee, et al.. (2020). A retrospective analysis of etiology and outcomes of hemophagocytic lymphohistiocytosis in children and adults. SHILAP Revista de lepidopterología. 38(3). 208–218. 6 indexed citations

14.

Byun, Ja Min, Junshik Hong, Doyeun Oh, et al.. (2020). Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia. Journal of Clinical Medicine. 9(7). 2310–2310.

15.

Kim, Won Seog, Cheolwon Suh, Jung Yong Hong, et al.. (2019). A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). Leukemia & lymphoma. 60(13). 3251–3257. 4 indexed citations

16.

Yun, Young Ho, Kyoung‐Nam Kim, Jin-Ah Sim, et al.. (2018). Comparison of attitudes towards five end-of-life care interventions (active pain control, withdrawal of futile life-sustaining treatment, passive euthanasia, active euthanasia and physician-assisted suicide): a multicentred cross-sectional survey of Korean patients with cancer, their family caregivers, physicians and the general Korean population. BMJ Open. 8(9). e020519–e020519. 24 indexed citations

17.

Lee, Won-Sik, Hyeoung‐Joon Kim, Jee Hyun Kong, et al.. (2017). Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Blood. 130. 1593–1593. 1 indexed citations

18.

Kım, Kihyun, Dok Hyun Yoon, Jin Seok Kim, et al.. (2014). Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. BioMed Research International. 2014. 1–7. 3 indexed citations

19.

Lee, Sung Sook, Cheolwon Suh, Bong-Seog Kim, et al.. (2010). Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. Annals of Hematology. 89(9). 905–912. 16 indexed citations

20.

Kim, Jong Gwang, Sang Kyun Sohn, Yee Soo Chae, et al.. (2008). TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemotherapy and Pharmacology. 64(2). 355–360. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact